SCHEMBL4026166

SCHEMBL4026166

C#CCNc1nc(Nc2ccc(C(C)=O)cc2)ncc1I

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.51
CCNB1 P14635 1/20 0.51
CCNE1 P24864 1/20 0.51
CDK2 P24941 1/20 0.51
CA2 P00918 1/20 0.51
CHEK1 O14757 2/20 0.49
SYK P43405 1/20 0.49
FLT3 P36888 1/20 0.49
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
MAPT P10636 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
EGFR P00533 2/20 0.42
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13648529 0.87 CDK1 (0.52) CDK1CCNB1CCNE1CDK2CA2
SCHEMBL4025895 0.86 CDK1 (0.70) CDK1CCNB1CCNE1CDK2CA2
SCHEMBL4021099 0.86 AURKA (0.55) CDK1CCNB1CCNE1CDK2CA2
SCHEMBL4068157 0.81 CA2 (0.78) CDK1CCNB1CCNE1CDK2CA2
SCHEMBL4016880 0.76 CHEK1 (0.45) CDK1CCNB1CCNE1CDK2CA2
SCHEMBL5169528 0.76 CHEK1 (0.45) CDK1CCNB1CCNE1CDK2CA2
SCHEMBL4016887 0.76 CHEK1 (0.45) CDK2CHEK1SYKFLT3NPC1
SCHEMBL3966386 0.76 CA2 (0.71) CDK1CCNB1CCNE1CDK2CA2
SCHEMBL13442815 0.75 CDK2 (0.59) CDK1CCNB1CCNE1CDK2CA2
SCHEMBL13897549 0.74 CDK1 (0.70) CDK1CCNB1CCNE1CDK2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598260-B2 CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-10-06 US disclosed
US-20080039447-A1 CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents BRUMBY THOMAS 2008-02-14 US disclosed
US-7291624-B2 CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2007-11-06 US disclosed
US-7235561-B2 Compound and a composition including such a compound SCHERING AG (DE) 2007-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039447-A1 CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents CDK2, CDK1, CDK6 CDK1 2/4885CCNB1 15/4885CCNE1 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.